Articles liés à Nasal Drug Delivery: Development and Evaluation of...

Nasal Drug Delivery: Development and Evaluation of Nasal Formulation - Couverture souple

Nanjwade, Basavaraj; A. Parikh, Kemy

 
9783848424382: Nasal Drug Delivery: Development and Evaluation of Nasal Formulation
Couverture souple
ISBN 10 : 384842438X ISBN 13 : 9783848424382
Editeur : LAP LAMBERT Academic Publishing, 2012

Synopsis

Microsphere carrier systems made from the biodegradable polymers have attracted considerable attention for several years in sustained drug delivery. However, the short residence time at the site of absorption could be overcome by coupling bioadhesion characteristics to microspheres and developing bioadhesive microspheres with the help of bioadhesive polymers. Neostigmine Bromide – a cholinesterase inhibitor is widely used for the treatment of Myasthenia Gravis. It is presently marketed in conventional dosage form as a tablet in usual strength of 15-30 mg for peroral route. Extent of absorption of drug through oral route is only 1-2% of 30 mg of administered dose. Hence there is need of novel nasal drug delivery system for the treatment of Myasthenia Gravis. To overcome inherent drawbacks associated with conventional dosage forms of Neostigmine Bromide, an attempt is being made in the present research work to develop an alternative drug delivery system in the form of Nasal mucoadhesive microspheres to increase the rate and extent of absorption and to reduce the dosing frequency of the formulation.

Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.

Présentation de l'éditeur

Microsphere carrier systems made from the biodegradable polymers have attracted considerable attention for several years in sustained drug delivery. However, the short residence time at the site of absorption could be overcome by coupling bioadhesion characteristics to microspheres and developing bioadhesive microspheres with the help of bioadhesive polymers. Neostigmine Bromide – a cholinesterase inhibitor is widely used for the treatment of Myasthenia Gravis. It is presently marketed in conventional dosage form as a tablet in usual strength of 15-30 mg for peroral route. Extent of absorption of drug through oral route is only 1-2% of 30 mg of administered dose. Hence there is need of novel nasal drug delivery system for the treatment of Myasthenia Gravis. To overcome inherent drawbacks associated with conventional dosage forms of Neostigmine Bromide, an attempt is being made in the present research work to develop an alternative drug delivery system in the form of Nasal mucoadhesive microspheres to increase the rate and extent of absorption and to reduce the dosing frequency of the formulation.

Biographie de l'auteur

Dr. Basavaraj K. Nanjwade has completed his Ph.D from Rajiv Gandhi University of Health Sciences Karnataka, Bangalore. He is the Director of KLE Society’s College of Pharmacy, Nipani, Karnataka, India. He has published 71 papers in reputed national and international journals and 12 Patents. He guided 19 M.Pharm and 7 Ph. D students.

Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.

Éditeur
LAP LAMBERT Academic Publishing
Date d'édition
2012
Langue
anglais
ISBN 10 
384842438X
ISBN 13 
9783848424382
Reliure
Broché
Nombre de pages
168
Coordonnées du fabricant
non disponible
Personne responsable
KreGa Onlinehandel GmbH
4950000000000
info@krega-onlinehandel.de

Birkenweg 31
Brakel
33034
Allemagne